AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
US approval gives Pfizer the first and second-line settings.
But, like Merck two weeks ago, GSK has failed to hit overall survival.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
